aibio
Company Updates ·
MetaVia to present Phase 1 DA-1726 data at Precision Liver Symposium
An abstract on the Phase 1 trial of DA-1726 was accepted for an oral presentation at the Precision Liver Symposium 2026 in Denver on November 4, 2026.
MTVA MetaVia Inc.
MetaVia (MTVA) news MTVA reverse split and offering news
Latest MetaVia news
- Company Updates
MetaVia appoints Sarah Browne as chief medical officer
Sarah Browne, M.D., joins MetaVia as Chief Medical Officer effective October 12, 2026, ahead of the fourth quarter 2026 topline readout from Part 3 of the DA-1726 Phase 1 trial.
- Company Updates
MetaVia reports DA-1726 tissue distribution data in preclinical study
A preclinical study found DA-1726-derived radioactivity concentrated in adipose tissue and retained over time, which MetaVia says supports the waist circumference reduction seen in clinical studies.
- Company Updates
MetaVia reports second quarter 2026 net loss of $5.3 million
MetaVia reported a net loss of $5.3 million for the quarter ended June 30, 2026, with cash and cash equivalents of $12.6 million, and said all active Part 3 patients reached their highest planned doses.
- Company Updates
MetaVia completes dose titration in Phase 1 Part 3 study of DA-1726
All active patients in both Part 3 cohorts of the DA-1726 obesity study reached target doses of 48 mg and 64 mg, and topline data remains on track for the fourth quarter of 2026.
- Financings
MetaVia files prospectus supplement for up to $4,000,000 in share sales
MetaVia filed a prospectus supplement for up to $4,000,000 of common stock under its at-the-market sales agreement with Ladenburg Thalmann & Co. Inc., dated November 6, 2025.
- Listings
MetaVia shareholders approve reverse split range of 1-for-5 to 1-for-22
At its June 8, 2026 annual meeting, MetaVia stockholders approved a reverse split of 5 to 22 shares into one, with the ratio left to the board, and 200,000 more shares for the equity plan.
- Company Updates
MetaVia reports DA-1726 mean weight reduction of 9.1% at 48 mg
In a late-breaking poster at the EASL Congress 2026, the company reported a 9.1% mean body-weight reduction at Day 54 in the 48 mg cohort, with no serious adverse events up to that dose.
- Company Updates
MetaVia to present three late-breaking abstracts at ADA 2026
Three posters, one on DA-1726 and two on vanoglipel, were accepted for the American Diabetes Association Scientific Sessions in New Orleans, June 5 to 8, 2026.
- Company Updates
MetaVia to present DA-1726 data as a late-breaking poster at EASL 2026
A late-breaking abstract on the obesity candidate DA-1726 was accepted for a poster at the EASL Congress 2026 in Barcelona, scheduled for May 27, 2026.
- Listings
MetaVia gets 180-day Nasdaq extension to May 26, 2026 on minimum bid price requirement
MetaVia Inc. (Nasdaq: MTVA) was granted more time to regain compliance after its stock closed below $1.00 for 30 consecutive trading days. It says a reverse stock split is an option.
- Listings
MetaVia gets Nasdaq minimum bid price notice, deadline November 25, 2025
The company's stock closed below $1.00 for 30 consecutive business days. It may be eligible for a second period of 180 calendar days.
- Financings
MetaVia closes private placement with about $10.0 million in gross proceeds
MetaVia sold 9,479,345 shares at $0.71 each and pre-funded warrants for 4,605,162 shares. Ladenburg Thalmann was the exclusive placement agent, for a cash fee of 9.0% of gross proceeds.
MetaVia annual financials
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $6.8 million | $21.6 million |
| Net income (loss) | -$13.0 million | -$27.6 million |
| Cash from operations | -$15.7 million | -$24.7 million |
| Cash and equivalents | $10.3 million | $16.0 million |
Questions about MetaVia
Did MetaVia do a reverse stock split?
Our latest story on this, dated Jun 8, 2026: "MetaVia shareholders approve reverse split range of 1-for-5 to 1-for-22". The story links the filing or release it is based on. Read the story.
Has MetaVia raised money recently?
Our latest story on this, dated Jul 2, 2026: "MetaVia files prospectus supplement for up to $4,000,000 in share sales". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of MetaVia?
MetaVia Inc. trades under the ticker MTVA on NASDAQ.
Where is MetaVia listed?
MetaVia Inc. is listed on NASDAQ.
What is the SEC CIK of MetaVia?
The SEC Central Index Key (CIK) for MetaVia Inc. is 1638287. Its filings are on SEC EDGAR.
How many shares does MetaVia have outstanding?
6,588,101 shares as of 2026-08-03, per the cover page of its 10-Q filed 2026-08-06.
Which country or territory is MetaVia listed under?
Our directory records MetaVia Inc. under United States.
What does MetaVia do?
Our directory classifies MetaVia Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
What is the ISIN of MetaVia?
The ISIN recorded for MetaVia Inc. is US64132R5037.
Does aibio.space cover MetaVia?
aibio.space lists MetaVia Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is MetaVia incorporated?
SEC records list its state or country of incorporation as DE.
Is MetaVia profitable?
MetaVia Inc. reported a net loss of $13.0 million for the fiscal year ended Dec 31, 2025, and used $15.7 million of cash in operations, per its annual report to the SEC.
How much does MetaVia spend on research and development?
$6.8 million in the fiscal year ended Dec 31, 2025, per its annual report.
How much cash does MetaVia have?
$12.6 million in cash at Jun 30, 2026, per its 10-Q.
What is the latest MetaVia (MTVA) stock news?
Our latest story on MetaVia, dated Oct 28, 2026: "MetaVia to present Phase 1 DA-1726 data at Precision Liver Symposium". An abstract on the Phase 1 trial of DA-1726 was accepted for an oral presentation at the Precision Liver Symposium 2026 in Denver on November 4, 2026. Source.
Investor discussion: MetaVia
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Capital-markets timeline
- Listings
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.02,5.07,9.01). Source
- Listings
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
- Listings
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
- Financings
Reported a financing. SEC Form 424B4. Source
- Financings
Filed a registration statement for a share offering. SEC Form S-1. Source
- Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
- Listings
Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,7.01,8.01,9.01). Source
- Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
- Listings
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
- Listings
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
- Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
- Listings
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
- Financings
Reported a financing. SEC Form 8-K (Items 1.01,3.02,8.01,9.01). Source
- Financings
Reported a financing. SEC Form 8-K (Items 5.03,7.01,8.01,9.01). Source
Stock chart
SEC filings and registration
- SEC name
- MetaVia Inc.
- CIK
- 1638287
- Industry (SIC)
- Pharmaceutical Preparations (2834)
- US tickers
- MTVA (Nasdaq)
- State or country of incorporation
- DE
- Fiscal year ends
- December 31
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Business address
- 545 CONCORD AVENUE, CAMBRIDGE, MA, 02138
- Phone
- (857) 702-9600
- Shares outstanding
- 6,588,101 as of 2026-08-03 (10-Q filed 2026-08-06)
- Former names
- NeuroBo Pharmaceuticals, Inc.; Gemphire Therapeutics Inc.
Recent filings
Listing details
- Company
- MetaVia Inc.
- Ticker
- MTVA
- Listing
- NASDAQ
- Country or territory
- United States
- Business scope
- Biotechnology
- ISIN
- US64132R5037
- Last quote in directory
- 2026-10-21
- Directory source
- Listing page
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction